HCC: Updates from ILCA and ESMO 2022

December 06, 2023 00:30:22
HCC: Updates from ILCA and ESMO 2022
COR2ED - Oncology Medical Conversation
HCC: Updates from ILCA and ESMO 2022

Dec 06 2023 | 00:30:22

/

Show Notes

In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented and discussed at the ILCA and ESMO congresses. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late breaking abstracts LEAP-002, RATIONALE-301 and tislelizumab monotherapy trials. The latter two studying first-line treatment with an anti-PD1 antibody with or without a kinase inhibitor in patients with advanced hepatocellular carcinoma. The experts evaluate and provide their insights into how to integrate these new treatments for HCC in the clinical practice.

Other Episodes

Episode

December 06, 2023 00:27:14
Episode Cover

Sarcoma: Updated bone sarcoma guidelines - Clinical implications

In this SARCOMA CONNECT Guidelines Podcast, two SARCOMA CONNECT Experts, Prof. Robert Maki and Prof. Silvia Stacchiotti, discuss recent updates in the ESMO and...

Listen

Episode

December 06, 2023 00:22:00
Episode Cover

Prostate cancer: Highlights from ASCO GU, ASCO and EAUN 2022

In this podcast Dr Jason Alcorn and Jennifer Sutton discuss the oncology nursing highlights from ASCO GU, ASCO and EAUN 2022.  The experts discuss:...

Listen

Episode

December 06, 2023 00:22:48
Episode Cover

Prostate cancer: Which mCSPC patients benefit from early treatment intensification? Case-based discussion

Assoc. Prof. Shilpa Gupta and Dr Fabio Schutz, discuss early treatment intensification with triplet therapy for metastatic castration-sensitive prostate cancer (mCSPC) in this GU...

Listen